Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Funding for startups developing small modular nuclear power plants looks like it’s beginning to dry up.
Apple plans to incentivize artists to use Dolby Atmos spatial-sound technology in their recordings by giving them more platform weight.
Occidental Petroleum, the oil giant in Berkshire Hathaway’s portfolio, announced it is acquiring CrownRock in a deal worth $12 billion.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
Following merger discussions two weeks ago, Humana and Cigna are walking away from what would’ve been the largest deal of the year.
“We’re moving away from the black box,” said said Frederick Gertz, founder and CEO of enterprise AI company Collide Technology.
The e-commerce luxury market has taken a big dip, placing the platforms that focus on luxury goods in hot water.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
StubHub’s latest Year in Live Experiences report found women captivated audiences in 2023 and generated massive ticket sales.
Exxon’s $60 billion planned acquisition of Pioneer Natural Resources has attracted the attention of the Federal Trade Commission.
Roche agreed Monday to acquire anti-obesity drug developer Carmot Therapeutics for an appetizing $3.1 billion.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.